FGFR2 and cholangiocarcinoma: The efficacy of pemigatinib on CCAs harboring FGFR alterations was further evaluated in the phase II study FIGHT-202.7 Patients with CCA and disease progression after at least 1 previous treatment was assigned to 1 of 3 cohorts: patients with FGFR2 fusions or rearrangements (n = 107), patients with other FGF/FGFR alterations (n = 20), or patients with no FGFR alterations (n = 18).